DRUG DISCOVERY
UNLEASHED

Let us unfold the target engagement of your compounds for unleashed drug discovery

CETSA® by Pelago offers accurate assessment of unmodified cellular target engagement throughout the drug discovery process – from early target identification and lead generation, to optimization and confirmation studies.

Our patented Celllular Thermal Shift Assays (CETSA®) provide quantitative measures of relevant target engagement and drug efficacy when you need it. Think of it as snapshots of genuine protein interactions, taken in a natural cell environment under actual physiological conditions .

Why accept unnecessary risk of delays and increased costs? When there is a method that allows you to see obstacles to efficacy before they appear?

This is CETSA®

Thermal shift assays (TSAs) are a well-established techniques for measuring ligand binding to purified proteins. They involve subjecting the protein to varying temperatures and quantifying its thermal denaturation. The key principle is that when a ligand is bound to a protein, the melting behaviour is altered, which is known as a ‘thermal shift’ and can be used to quantify the affinity of the ligand-protein interaction.

”Perhaps the most important unique benefit of using CETSA® during lead generation is that it allows you to directly discard false positives, allowing you to fail faster and prioritize only the very best compounds”

Stina Lundgren, Drug Discovery Expert

CETSA® (Cellular Thermal Shift Assay) is based on this fundamental principle but leverages the novel insight that the melt curves can be generated in intact cells and tissues.
Adopting CETSA® early can reduce your project timeline by 6-12 months and expedite the progress of projects throughout the drug discovery pipeline.

Welcome to Pelago Bioscience
The Home of CETSA®

Book a meeting now

Send us your contact info and we will get back to you via e-mail





    Want to learn more